JPS59175469A - ピラゾロン誘導体のリポキシゲナ−ゼ禁止剤としての使用 - Google Patents

ピラゾロン誘導体のリポキシゲナ−ゼ禁止剤としての使用

Info

Publication number
JPS59175469A
JPS59175469A JP59046368A JP4636884A JPS59175469A JP S59175469 A JPS59175469 A JP S59175469A JP 59046368 A JP59046368 A JP 59046368A JP 4636884 A JP4636884 A JP 4636884A JP S59175469 A JPS59175469 A JP S59175469A
Authority
JP
Japan
Prior art keywords
group
carbon atoms
optionally
formula
hydrogen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP59046368A
Other languages
English (en)
Japanese (ja)
Inventor
ミタト・マルデイン
フリ−デル・ゾイタ−
エリ−ザベト・ペルツボルン
クラウス・シユロスマン
デイ−タ−・マイヤ−
フオルカ−・フイ−ドラ−
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer AG filed Critical Bayer AG
Publication of JPS59175469A publication Critical patent/JPS59175469A/ja
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP59046368A 1983-03-12 1984-03-10 ピラゾロン誘導体のリポキシゲナ−ゼ禁止剤としての使用 Pending JPS59175469A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19833308881 DE3308881A1 (de) 1983-03-12 1983-03-12 Verwendung von pyrazolonderivaten als lipoxygenasehemmer, bei der therapie von ischaemien und herzrhythmusstoerungen sowie von rheumatischen, allergischen und asthmatischen erkrankungen, oedemen, lungenembolien, pulmonaler hypertension, sauerstoffintoxikation und ulcerationen, arzneimittel hierfuer und verfahren zu deren herstellung
DE33088810 1983-03-12
DE33426287 1983-11-25

Publications (1)

Publication Number Publication Date
JPS59175469A true JPS59175469A (ja) 1984-10-04

Family

ID=6193304

Family Applications (1)

Application Number Title Priority Date Filing Date
JP59046368A Pending JPS59175469A (ja) 1983-03-12 1984-03-10 ピラゾロン誘導体のリポキシゲナ−ゼ禁止剤としての使用

Country Status (4)

Country Link
JP (1) JPS59175469A (de)
KR (1) KR840008326A (de)
DE (1) DE3308881A1 (de)
ZA (1) ZA841766B (de)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35801E (en) * 1985-05-20 1998-05-19 Mitsubishi Chemical Corporation Prophylactic and therapeutic composition for circulatory disorders and method of treatment

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970210A (en) * 1987-07-17 1990-11-13 Abbott Laboratories Triazinone lipoxygenase compounds
BRPI0815597A2 (pt) * 2007-11-21 2014-09-30 Teikoku Pharma Usa Inc Formulações de emulsões com derivado de pirazolona

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE35801E (en) * 1985-05-20 1998-05-19 Mitsubishi Chemical Corporation Prophylactic and therapeutic composition for circulatory disorders and method of treatment

Also Published As

Publication number Publication date
KR840008326A (ko) 1984-12-14
DE3308881A1 (de) 1984-09-13
ZA841766B (en) 1984-10-31

Similar Documents

Publication Publication Date Title
Levi et al. Acetyl glyceryl ether phosphorylcholine (AGEPC). A putative mediator of cardiac anaphylaxis in the guinea pig.
JPS61236778A (ja) 5−置換ピラゾロ〔4,3−d〕ピリミジン−7−オン
JP3071820B2 (ja) アナフィラキシーの遅反応性物質に対する拮抗薬としてのリポキシンa▲下4▼およびその誘導体の使用
Brezinski et al. Anti-ischemic actions of a new throm☐ ane receptor antagonist during acute myocardial ischemia in cats
Schrör et al. Treatment of acute myocardial ischaemia with a selective antagonist of thromboxane receptors (BM 13.177).
JPH04503524A (ja) 再潅流損傷の防止又は制限のための薬剤
US4694018A (en) Substituted 1,5-diphenyl-2-pyrrolepropionic acids and derivatives
DE69736130T2 (de) Pharmazeutische produkte zur heilung und vorbeugung von krankheiten, die aus der beschädigung der vaskulären endothelzellen hervorgehen
JPH0518831B2 (de)
US4670460A (en) Inhibiting lipoxygenase with pyrazolone derivatives
US4661484A (en) Pyridazinone derivatives and salts thereof as cardiac stimulants
JPS59175469A (ja) ピラゾロン誘導体のリポキシゲナ−ゼ禁止剤としての使用
Toga et al. Vascular effects of platelet-activating factor in lambs: role of cyclo-and lipoxygenase
US4659732A (en) Lipoxygenase inhibiting 1-arylalkyl-, 1-arylthio-, and 1-aryloxypyrazole-4,5-diones
JPS6144883A (ja) 4h−1,4−ベンゾチアジン類の用途
PL94060B1 (en) Fused-ring isoquinoline derivatives[gb1438819a]
US4657924A (en) Nafazatrom as a lipoxygenase inhibitor
JPS59141517A (ja) ナフアザトロム含有薬剤
Kosakai et al. Pharmacologic properties of KT2–962 (6-isopropyl-3-[4-(p-chlorobenzenesulfonylamino)-butyl]-azulene-1-sulfonic acid sodium salt); a new TXA2/prostaglandin endoperoxide receptor antagonist
JPS59196870A (ja) 腫瘍細胞の成長および転移の形成の防除におけるピラゾロン誘導体類およびこのための薬物および新規なピラゾロン誘導体類
JP2677382B2 (ja) ロイコトリエン拮抗剤
TWI246424B (en) Use of 2-imidazolyl-substituted carbinols for the production of a medicament for the treatment or prophylaxis of diseases caused by ischemic conditions
KR0135034B1 (ko) 신규한 2-클로로-3-아릴아미노-1,4-나프토퀴논 유도체, 그의 제조방법 및 그의 혈소판 응집억제제로서의 용도
JPH0586389B2 (de)
DE3342628A1 (de) Verwendung von pyrazolonderivaten als lipoxygenasehemmer bei der therapie von ischaemien und herzrhythmusstoerungen, haut- und augenentzuendungen, sowie von rheumatischen, allergischen und asthmatischen erkrankungen, oedemen, lungenembolien, pulmonaler hypertension, schocklunge, sauerstoffintoxikation und ulcerationen, arzneimittel hierfuer und verfahren zu deren herstellung